Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) are common viruses that can cause respiratory infections, especially in young children and infants. Meridian is conducting a clinical trial for a combined investigational vaccine for hMPV and PIV3.
- Must be children age 12 to 59 months
- May receive compensation for time and travel
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for your child.
You can also talk to a Meridian enrollment specialist about this study by calling (402) 934-7563 (NE) or (912) 623-2240 (NY, WDC).
Submit your information
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services.
Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For almost 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.